Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2025Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

EAEmanuele AngelucciOspedale Policlinico San MartinoÉDÉric DeconinckInsermTBTobias Matthieu BenoitUniversity Hospital of Zurich

Discussion

Loading...

Member takes

Implication

Observational analysis reports a 65% overall response rate in adults with relapsed BPDCN, highlighting safety and efficacy of tagraxofusp.

Key Points

  • A 65% overall response rate was observed in relapsed/refractory BPDCN patients treated with tagraxofusp, indicating promising efficacy.
  • Patients treated with tagraxofusp experienced a median overall survival of 8.4 months, demonstrating potential benefits for this high-risk population.
  • The safety profile revealed manageable capillary leak syndrome, primarily occurring during the first treatment cycle.
  • Outcomes support tagraxofusp's potential role as a bridge to stem cell transplant for BPDCN patients after chemotherapy.

Cite This Study

Angelucci et al. (2025) studied this question.

synapsesocial.com/papers/68d466a831b076d99fa64fd7https://doi.org/10.1080/10428194.2025.2553862
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Confidence Interval for the Median Survival Time1982 · 925 citations
  2. 2Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival2024 · 12 citations
  3. 3Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia2003 · 2,686 citations
  4. 4Blastic Plasmacytoid Dendritic Cell Neoplasm2023 · 44 citations